成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Home Cart Sign in  
Chemical Structure| 313516-66-4 Chemical Structure| 313516-66-4
Chemical Structure| 313516-66-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

{[proInfo.proName]}

CAS No.: 313516-66-4

,{[proInfo.pro_purity]}

T0070907 serves as a potent antagonist of PPARγ, with a Ki of 1 nM.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support Online Technical Q&A
Product Citations

Alternative Products

Product Details of T0070907

CAS No. :313516-66-4
Formula : C12H8ClN3O3
M.W : 277.66
SMILES Code : O=C(NC1=CC=NC=C1)C2=CC([N+]([O-])=O)=CC=C2Cl
MDL No. :MFCD00121849
InChI Key :FRPJSHKMZHWJBE-UHFFFAOYSA-N
Pubchem ID :2777391

Safety of T0070907

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H319
Precautionary Statements:P305+P351+P338

Isoform Comparison

Biological Activity

Target

  • PPARγ

    PPARγ, IC50:1 nM

In Vitro:

Cell Line
Concentration Treated Time Description Reference
HEK293 cells 0.3, 1, 3, 10, 30 μM 18 h ELB00824 exhibited in vitro anti-oxidative activity in HEK293 cells similar to typical clinically used PPAR γ agonists. PMC9574783
WM4265.2-BrM1 cells 10μM 48 h PPARγ antagonist inhibited the growth of WM4265.2-BrM1 cells PMC6891206
MDA231-BrM cells 10μM 48 h PPARγ antagonist inhibited the proliferation of MDA231-BrM cells PMC6891206
BV2 cells 5 μM 20 h To evaluate the anti-inflammatory effects of VCE-003.2 in LPS-exposed BV2 cells, results showed that VCE-003.2 could reduce the release of TNF-α and IL-1β PMC5771072
M-213 cells 0.1, 0.5, 1 μM 40 h To evaluate the neuroprotective effects of VCE-003.2 in M-213 cells, results showed that low concentrations of VCE-003.2 could reduce cell death PMC5771072
Mouse primary microglia cells 1 μM 15 h MA showed strong anti-inflammatory effects in LPS-stimulated microglia, significantly reducing the expression of IL-6, iNOS, MCP-1, and TNF-α, and increasing the expression of IL-10. PMC4378556
ILC2s 2 μM 48 h To investigate the effect of T0070907 on cytokine secretion in ILC2s, results showed that T0070907 significantly reduced IL-13 secretion. PMC8100153
Th17 cells 2 μM 3 days To study the effect of T0070907 on Th17 cell polarization, results showed that T0070907 inhibited Th17 cell polarization. PMC9720675
HPAC cells 5 or 10 μM 72 h T0070907 inhibited the transcriptional activity of PPARγ and suppressed the proliferation and colony-formation capacity of HPAC and SW1990 cells. PMC8847684
SW1990 cells 5 or 10 μM 72 h T0070907 inhibited the transcriptional activity of PPARγ and suppressed the proliferation and colony-formation capacity of HPAC and SW1990 cells. PMC8847684
PANC-1 cells 5 or 10 μM 72 h T0070907 inhibited cell proliferation in PANC-1 cells but had no effect on cell growth and body weight in vivo. PMC8847684

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description Reference
BALB/c mice Acute or chronic chemotherapy-induced neuropathic pain model Intraperitoneal injection 30 mg/kg Once daily for 5 consecutive days ELB00824 significantly reduced oxaliplatin-induced cold hyperalgesia and mechanical allodynia and oxidative stress. PMC9574783
Mice High-fat diet-induced obesity model Intraperitoneal injection 2 mg/kg Single dose, lasting 1 day To verify whether PRMT4-mediated white adipose tissue browning is dependent on PPARγ, the results showed that T0070907 inhibited PRMT4-induced thermogenic gene expression and cold tolerance. PMC10382653
mice brain metastasis models intraperitoneal injection 5 mg/kg daily, for 28 days PPARγ antagonist significantly reduced brain metastatic burden PMC6891206
C57BL/6 mice LPS-induced Parkinson's disease model intraperitoneal injection 10 mg/kg once daily for 21 days To evaluate the anti-inflammatory and neuroprotective effects of VCE-003.2 in LPS-lesioned mice, results showed that VCE-003.2 could reduce microglial activation and the loss of TH-positive neurons PMC5771072
Kunming mice Middle cerebral artery occlusion model (MCAO) in mice Caudal vein injection 2 mg/kg Single dose 1 h before MCAO surgery T0070907 significantly reversed the protective effects of MA in MCAO mice, increased infarct size, and influenced the M1/M2 phenotype of microglia/macrophages. PMC4378556
Mice PPAR γflox/floxId2-CreERT2 mice Intraperitoneal injection 7.5 mg/kg Once daily for 18 days To investigate the effect of T0070907 on tumor growth, results showed that T0070907 significantly reduced tumor volume and weight. PMC8100153
BALB/c nu/nu mice Pancreatic cancer xenograft model Gavage 5 mg/kg Three times a week for four weeks T0070907 inhibited tumor growth without affecting the of mice. PMC8847684

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.60mL

0.72mL

0.36mL

18.01mL

3.60mL

1.80mL

36.02mL

7.20mL

3.60mL
Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories